Genmab — August 2018

[F_L]

I know that after the Callisto failure things changed on the solid side. Just have a question one step back on why Genmab was targetting that market. I know the lung cancer market is a huge market. On the other hand there are other drugs/ther being developed which are a lot cheaper. From a cost/effectiveness (Dara) point of view, was it interesting enough to target it in the first place, ie could Dara have made a big difference vs the other new medicines? Didn't look at the ph1 data in detail.

[Helge_LarsenPI-redaktør]

FL...Welcome to Proinvestor. Maybe you should find a different alias than F L. It will easily be confused with E L.

[Mcjean]

JNJ own the rights for Dara, Genmab only get Royalties and milestones so Its JNJ there decide the indikation profile........if i understand u question correct.

[F_L]

"Helge, thank you. I have no intention to post frequently.

[F_L]

@ McJean sorry I meant JNJ. It surprised me they wanted to look at Dara in lung cancer given all the other cheaper therapies that are being developed.

[Plimsoller]

God morgen

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[transalp]

go morgen

[pauly]

mornings

[polle1]

God morgen

[Parasitism]

God Morgen

[gentogen]

Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. June 7, 2018
New England Journal of Med. 2018; 378:2240-2242

[bibob]

Gentogen. Har du et link. ?

[hda]

Just a moment...

(www.nejm.org)

[bibob]

Tak hda. Det lyder da virkelig lovende.

[nohope]

2 patienter -

[E_L]

yes, extremely small disease, we discussed June 7. But it keeps up hope that one day they find it will also work for a bigger disease

[E_L]

The Janssen BCMA CD3 DuoBody was not mentioned in the call was it? Would we expect any data on this this year? Estimated Primary Completion Date is: November 1, 2018

[E_L]

this one https://clinicaltrials.gov/ct2/show/NCT03145181